Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study)

In virologically suppressed individuals, maintaining DTG/3TC or switching to BIC/FTC/TAF demonstrated equivalent profiles with respect to systemic inflammation, metabolic outcomes, and immunologic markers over 96 weeks.

Authors

Institutions

Publication Details

Journal
Clinical Infectious Diseases
Published
2025-10-09
DOI
https://doi.org/10.1093/cid/ciaf565
Citations
4
Primary Topic
HIV-related health complications and treatments
Type
article
Field-Weighted Citation Impact
9.01
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study)

Vicente Estrada, Laura Martín‐Pedraza, Alfonso Cabello, Juan Tiraboschi et al.
4 citations
Clinical Infectious Diseases
HIV-related health complications and treatments
9.01
article

Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study)

Vicente Estrada, Laura Martín‐Pedraza, Alfonso Cabello, Juan Tiraboschi, Joaquín Burgos, Jesús Troya, Luís F. López‐Cortés, Carmen Busca, José Ramón Blanco, Ana del Amo-de Palacios, Sergio Serrano‐Villar, Carmen Hidalgo‐Tenorio, Jesús Santos, Marta Montero, María José Crusells, Miguel Torralba, Santiago Moreno, Enrique Bernal, Marta de Miguel, Alberto Díaz de Santiago, María Novella, María Fons-Contreras
article en
4 citations

Abstract

In virologically suppressed individuals, maintaining DTG/3TC or switching to BIC/FTC/TAF demonstrated equivalent profiles with respect to systemic inflammation, metabolic outcomes, and immunologic markers over 96 weeks.

Clinical Infectious DiseasesVol. 82(2)
Hebron University (PS), Universidad de Alcalá (ES), Instituto Cajal (ES), Hospital Universitario La Paz (ES), Bellvitge University Hospital (ES), Hospital Clínico San Carlos (ES), Hospital Universitari i Politècnic La Fe (ES), Universidad Nebrija (ES), Hospital Universitario de Guadalajara (ES), Centro de Investigación en Red en Enfermedades Cardiovasculares (ES), Hospital Universitario Puerta de Hierro Majadahonda (ES), Hospital Universitario Príncipe de Asturias (ES), Instituto de Investigación Biosanitaria de Granada (ES), Centro de Investigación Biomédica en Red (ES), Hospital Universitario Virgen de las Nieves (ES), Fundación Seimc-Gesida (ES), Complejo Hospitalario Universitario de Granada (ES), Instituto Ramón y Cajal de Investigación Sanitaria (ES), Vall d'Hebron Hospital Universitari (ES), Hospital Universitario Fundación Jiménez Díaz (ES), Hospital Reina Sofía de Murcia (ES), Instituto de Biomedicina de Sevilla (ES), Hospital Clínico Universitario Lozano Blesa (ES), Hospital San Pedro (ES), Center for Biomedical Research of La Rioja (ES), Hospital Universitario Virgen del Rocío (ES), Hospital Clínico Universitario Virgen de la Victoria (ES), Instituto de Investigación Biomédica de Málaga (ES), Hospital Universitario Infanta Leonor (ES), Universidad Autónoma de Madrid (ES)
Openalex Percentile: Top 2%
HIV-related health complications and treatments
9.01
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.